Aliihsan Gemici
Overview
Explore the profile of Aliihsan Gemici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atas U, Salim O, Iltar U, Yucel O, Kucukdiler Eroglu A, Aslan V, et al.
Turk J Haematol
. 2024 Nov;
41(4):225-235.
PMID: 39501735
Objective: In this study, we aimed to obtain real-life data on the use of antimyeloma agents, which significantly increase overall survival (OS) in multiple myeloma (MM) patients, in primary plasma...
2.
Mutlu Y, Aydin B, Erdogan C, Kizilaslan D, Bekoz H, Gemici A, et al.
Indian J Hematol Blood Transfus
. 2023 Apr;
39(2):167-172.
PMID: 37006979
Introduction: To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care unit...
3.
Karakus V, Maral S, Kaya E, Gemici A, Dere Y, Sevindik O
North Clin Istanb
. 2022 Oct;
9(4):331-336.
PMID: 36276561
Objective: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life...
4.
Eren R, Serin I, Atak S, Pirdal B, Nizam N, Gemici A, et al.
Indian J Hematol Blood Transfus
. 2022 Oct;
39(2):191-199.
PMID: 36186233
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment....
5.
Gemici A, Ozkalemkas F, Dogu M, Tekinalp A, Alacacioglu I, Guney T, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Jun;
21(8):e686-e692.
PMID: 34059487
Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in...
6.
Gemici A, Bilgen H, Erdogan C, Kansu A, Olmuscelik O, Bekoz H, et al.
Turk J Med Sci
. 2020 Oct;
50(8):1781-1785.
PMID: 33078604
Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19....
7.
Gemici A, Aydogdu I, Terzi H, Sencan M, Aslan A, Kaya A, et al.
Hematol Oncol
. 2017 Jul;
36(1):116-120.
PMID: 28707314
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL...